Rezolute Inc (RZLT)

$9.87 -0.07 (-0.70%)
Market Cap 921.72M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,310,100
Avg Vol 1,503,958
Day's Range N/A - N/A
Shares Out 92.73M
Stochastic %K 46%
Beta 0.07
Analysts Strong Sell
Price Target $15.22

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
RNASequencing
RNASequencing Nov. 15 at 2:03 AM
$RZLT going on the record here takeout <6 months at >$20 per share post sunRIZE readout in December
0 · Reply
TMoney07__
TMoney07__ Nov. 14 at 6:36 PM
$RZLT Anyone selling right now is gonna feel stupid when positive data in December gaps this to $20+ 😅
2 · Reply
ACES_
ACES_ Nov. 14 at 6:03 PM
$RZLT back to the buy zone...
1 · Reply
TMoney07__
TMoney07__ Nov. 14 at 4:32 PM
$RZLT XBI is at ATH’s, no reason we shouldn’t close over 10 today. We probably get some type of run later today, maybe to the 10.50 area?
0 · Reply
Monty3030
Monty3030 Nov. 14 at 3:33 PM
$RZLT With that Merck deal today, goes to show you that a company can be acquired before phase 3 readout! Let's see if RZLT will get an offer with 3-4 weeks left before readout.
0 · Reply
oaksapollo
oaksapollo Nov. 14 at 3:15 PM
$RZLT so much M&A in pharma these days. Seems like every week there are at least a few deals announced (today it's Cidara+Merck). When will it be our turn? I think not long after data, a deal is announced, 1H 2026.
0 · Reply
TMoney07__
TMoney07__ Nov. 14 at 2:58 PM
$RZLT 9.70 support is strong, seems like that’s the lowest we’ll go with this market sentiment. Any market recovery and we’re likely sitting nicely in the 10’s or 11’s. It really doesn’t matter though, because we’ll run nicely either way if data is good.
1 · Reply
Drashkawisha
Drashkawisha Nov. 14 at 12:11 PM
$RZLT The Case: Phase 3 "riTRe" study (RZ358) for congenital hyperinsulinism (CHI). Fact: This is a pre-data momentum play. The thesis is built on strong Phase 2b data which showed RZ358 achieved its primary endpoint (significant reduction in hypoglycemia).
0 · Reply
Eaglelanded
Eaglelanded Nov. 14 at 12:11 PM
$RZLT $CDTX today - $RZLT tomorrow !
0 · Reply
Fugazi_
Fugazi_ Nov. 13 at 7:21 PM
$RZLT odds for data next week
2 · Reply
Latest News on RZLT
Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Nov 10, 2025, 7:51 PM EST - 4 days ago

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 4 days ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 8 days ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 9 days ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Participate in Upcoming Investor Conferences

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 17, 2025, 4:05 PM EDT - 2 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Sep 16, 2025, 4:36 PM EDT - 2 months ago

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 12, 2025, 9:38 AM EDT - 2 months ago

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Aug 20, 2025, 7:30 AM EDT - 3 months ago

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 4 months ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 4 months ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 6 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 6 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 6 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 7 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 7 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Apr 23, 2025, 3:50 PM EDT - 7 months ago

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Apr 23, 2025, 8:05 AM EDT - 7 months ago

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Apr 23, 2025, 8:00 AM EDT - 7 months ago

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Mar 26, 2025, 7:30 AM EDT - 8 months ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 18, 2025, 1:30 AM EST - 9 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 9 months ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Feb 4, 2025, 8:00 AM EST - 10 months ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 10 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2024, 8:00 AM EST - 1 year ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Dec 3, 2024, 3:56 PM EST - 1 year ago

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 19, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Sep 9, 2024, 10:41 AM EDT - 1 year ago

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Sep 9, 2024, 7:47 AM EDT - 1 year ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Sep 9, 2024, 7:30 AM EDT - 1 year ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 11:30 PM EDT - 1 year ago

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Rezolute to Participate in the Jefferies Global Healthcare Conference

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 21, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Mar 6, 2024, 7:30 AM EST - 1 year ago

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Feb 13, 2024, 4:05 PM EST - 1 year ago

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Jan 24, 2024, 8:00 AM EST - 1 year ago

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Jan 23, 2024, 8:00 AM EST - 1 year ago

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Dec 13, 2023, 8:00 AM EST - 2 years ago

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Nov 24, 2023, 11:14 AM EST - 2 years ago

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Nov 17, 2023, 8:00 AM EST - 2 years ago

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Rezolute Reports First Quarter Fiscal 2024 Results

Nov 13, 2023, 4:05 PM EST - 2 years ago

Rezolute Reports First Quarter Fiscal 2024 Results

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Nov 9, 2023, 6:57 PM EST - 2 years ago

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

RNASequencing
RNASequencing Nov. 15 at 2:03 AM
$RZLT going on the record here takeout <6 months at >$20 per share post sunRIZE readout in December
0 · Reply
TMoney07__
TMoney07__ Nov. 14 at 6:36 PM
$RZLT Anyone selling right now is gonna feel stupid when positive data in December gaps this to $20+ 😅
2 · Reply
ACES_
ACES_ Nov. 14 at 6:03 PM
$RZLT back to the buy zone...
1 · Reply
TMoney07__
TMoney07__ Nov. 14 at 4:32 PM
$RZLT XBI is at ATH’s, no reason we shouldn’t close over 10 today. We probably get some type of run later today, maybe to the 10.50 area?
0 · Reply
Monty3030
Monty3030 Nov. 14 at 3:33 PM
$RZLT With that Merck deal today, goes to show you that a company can be acquired before phase 3 readout! Let's see if RZLT will get an offer with 3-4 weeks left before readout.
0 · Reply
oaksapollo
oaksapollo Nov. 14 at 3:15 PM
$RZLT so much M&A in pharma these days. Seems like every week there are at least a few deals announced (today it's Cidara+Merck). When will it be our turn? I think not long after data, a deal is announced, 1H 2026.
0 · Reply
TMoney07__
TMoney07__ Nov. 14 at 2:58 PM
$RZLT 9.70 support is strong, seems like that’s the lowest we’ll go with this market sentiment. Any market recovery and we’re likely sitting nicely in the 10’s or 11’s. It really doesn’t matter though, because we’ll run nicely either way if data is good.
1 · Reply
Drashkawisha
Drashkawisha Nov. 14 at 12:11 PM
$RZLT The Case: Phase 3 "riTRe" study (RZ358) for congenital hyperinsulinism (CHI). Fact: This is a pre-data momentum play. The thesis is built on strong Phase 2b data which showed RZ358 achieved its primary endpoint (significant reduction in hypoglycemia).
0 · Reply
Eaglelanded
Eaglelanded Nov. 14 at 12:11 PM
$RZLT $CDTX today - $RZLT tomorrow !
0 · Reply
Fugazi_
Fugazi_ Nov. 13 at 7:21 PM
$RZLT odds for data next week
2 · Reply
TMoney07__
TMoney07__ Nov. 13 at 7:05 PM
$RZLT This market is so ass 🤣 don’t think we dip much lower with data around the corner, or a quick recovery if we did. December can’t come any quicker.
1 · Reply
ACES_
ACES_ Nov. 13 at 3:12 PM
$RZLT bit
0 · Reply
ACES_
ACES_ Nov. 13 at 3:08 PM
$RZLT lil ankle biting fuckers...
0 · Reply
TMoney07__
TMoney07__ Nov. 13 at 2:50 PM
$RZLT If we’re gonna have bad market sentiment, i’d rather it be now than closer to the readout. Market probably bounces back in Dec & we have good overall sentiment going into the readout.
0 · Reply
Zyntax
Zyntax Nov. 13 at 9:13 AM
$RZLT One way this would definitely pop up is that if they announce that they have bought some cryptos to enhance their cash position even further from current one but it’s also risky.
2 · Reply
Monty3030
Monty3030 Nov. 13 at 1:46 AM
$RZLT Government shutdown is officially over! Let's see if we hit $12 tomorrow!!
1 · Reply
Monty3030
Monty3030 Nov. 12 at 7:07 PM
$RZLT This play is getting very interesting. Could we 2x, 3x, 4x and maybe even 5x from the $10-$12 price range once data is released....
2 · Reply
ACES_
ACES_ Nov. 12 at 4:46 PM
$RZLT Data coming within weeks... them playing checkers... we play 7D chess... we will win.
0 · Reply
oaksapollo
oaksapollo Nov. 12 at 3:34 PM
$RZLT I just sold 10 covered calls for Jan with a $22.50 strike for $0.80. That seems crazy. I placed the order not expecting it to be filled. I win either way. If it never touches $22.50, it's free money. If it really goes that high, then my position is worth millions and I am also okay with that outcome ;-)
1 · Reply
oaksapollo
oaksapollo Nov. 12 at 3:15 PM
$RZLT The drug clearly works based on compassionate use data and phase 2. My only worry is whether there is some chance the phase 3 fails due to some stupid technical reason. Anyone have thoughts on this?
2 · Reply
Quantumup
Quantumup Nov. 12 at 1:19 PM
JonesTrading⬆️ $RZLT's PT to $14 from $12 and reiterated at a Buy rating. $ZLDPF $CRNX $AMLX Here's what JonesTrading had to say in its note:
0 · Reply
TMoney07__
TMoney07__ Nov. 12 at 10:20 AM
$RZLT Adding to my post below… their drug is going into a crowded market, RZLT’s (ersodetug) is in an area of unmet need & zero competition. Positive data in Dec would likely be more significant than COGT's, both in clinical impact and commercial upside potential. No reason we can’t see a move like that, if not higher.
1 · Reply